Latest News about BIIB
Recent news which mentions BIIB
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
September 09, 2023
From Motley Fool
From InvestorPlace
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
September 06, 2023
From Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
September 06, 2023
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
From Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
From Benzinga
The 3 Best Biotech Stocks to Buy Now: September 2023
September 04, 2023
From InvestorPlace
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
September 04, 2023
Tickers
BIIB
From Benzinga
The 7 Most Promising Momentum Stocks to Own Now
August 31, 2023
From InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
August 30, 2023
From InvestorPlace
Better Buy: Biogen vs. Eli Lilly
August 29, 2023
From Motley Fool
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
August 28, 2023
From Motley Fool
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
August 24, 2023
From InvestorPlace
From Motley Fool
Why Shares of Sage Therapeutics Slumped This Week
August 11, 2023
From Motley Fool
Tickers
BIIB
From Motley Fool
With an Acquisition on the Way, Is Biogen Stock a Buy?
August 09, 2023
From Motley Fool
Is Sage Therapeutics a Contrarian Buy?
August 08, 2023
From Motley Fool
From Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
August 07, 2023
From Benzinga
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
August 07, 2023
From Benzinga
Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder
August 07, 2023
From MarketWatch
From Benzinga
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
August 07, 2023
From Benzinga
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.